AIM
SRNE

Advantage Investment Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Advantage Investment Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$2K Hold
850
– – ﹤0.01% 872
2019
Q2 		$2K Hold
850
– – ﹤0.01% 882
2019
Q1 		$4K Hold
850
– – ﹤0.01% 811
2018
Q4 		$2K Hold
850
– – ﹤0.01% 928
2018
Q3 		$4K Hold
850
– – ﹤0.01% 886
2018
Q2 		$6K Hold
850
– – ﹤0.01% 750
2018
Q1 		$4K Buy
+850
New +$6.05K ﹤0.01% 848

Other funds holding SRNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Advantage Investment Management's SRNE Position: Q3 2019 in Review

Advantage Investment Management held its Sorrento Therapeutics, Inc. (SRNE) position steady in Q3 2019 at 850 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #872.

Advantage Investment Management first reported a position in SRNE in Q1 2018 and has held it in 7 quarters since. The position peaked at $6K in Q2 2018. 85 funds tracked by Wall St. Rank hold SRNE as of Q3 2019.

  • Advantage Investment Management held 850 shares of Sorrento Therapeutics, Inc. worth $2K as of Q3 2019.
  • Advantage Investment Management left its Sorrento Therapeutics, Inc. share count unchanged in Q3 2019.
  • Sorrento Therapeutics, Inc. made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #872 holding.
  • Advantage Investment Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2018 and has held it in 7 quarters since.
  • Advantage Investment Management's Sorrento Therapeutics, Inc. position peaked at $6K in Q2 2018.
  • 85 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.